The "Red Line" Checklist for Serum Efficacy Claims: Regulatory Boundaries for Anti-Wrinkle / Firming / Spot-Lightening

I. A Single Claim Can Turn Your Product from a "Cosmetic" into an "Unapproved Drug"

"Rebuild deep skin structure," "reverse aging," "cellular-level repair"—these claims are common on serum product pages, sounding highly persuasive, yet they can trigger the most severe compliance alarms in international markets.

The core logic of cosmetic regulations is highly consistent across major global markets: cosmetics can only alter appearance, not bodily functions or structures. Once a claim crosses this line, the product shifts from a cosmetic to a drug or medical device—meaning entirely different registration systems, clinical trial requirements, and market approval processes.

The US FDA's core distinction is clear: Cosmetics are "articles intended to be rubbed, poured, sprinkled, or sprayed on, introduced into, or otherwise applied to the human body... for cleansing, beautifying, promoting attractiveness, or altering the appearance" (e.g., anti-wrinkle creams). Drugs are "articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease" (e.g., acne treatments, antibiotic creams). If a product is marketed with disease-treating or preventing claims, it is deemed a drug and requires FDA pre-market approval.

For the serum category, the three highest-frequency efficacy directions—"anti-wrinkle," "firming," and "spot-lightening"—are precisely the areas with the densest regulatory red lines.

II. "Anti-Wrinkle / Anti-Aging" Claims: Appearance Improvement vs. Structural Alteration

Compliance Zone (Safe to Use)

• "Reduces the appearance of fine lines"

• "Wrinkles appear less visible"

• "Skin looks firmer"

• "Improves skin texture"

Red Line Zone (Must Avoid)

The following types of claims will classify the product as a drug:

• Claims that the product "counteracts," "retards," or "controls" the aging process.

• Claims that the product "rejuvenates," "repairs," or "restructures" the skin.

• Claims implying internal structural changes, such as "molecules absorb and swell, pushing upward to 'lift' wrinkles."

These can be classified as drug claims by the FDA. The FDA has previously issued warning letters to major brands like Avon and Lancôme specifically regarding their anti-aging and anti-wrinkle claim wording.

EU Perspective: Under the EU Common Criteria (Regulation 655/2013), efficacy claims must describe positive effects expected after product use, be supported by scientific evidence, and not be misleading. The EU also clearly distinguishes "improving appearance" (cosmetic) from "altering skin function" (illegal/drug claim). Claims like brightening skin tone or strengthening nails (altering appearance) are compliant, while claims of fundamentally altering skin structure cross into drug territory.

III. "Firming / Lifting" Claims: Physical Sensation vs. Biological Mechanism

Compliant Expressions

• "Immediate tightening feeling"

• "Skin looks firmer and more elastic"

• "Improves the appearance of facial contours"

High-Risk Expressions to Note

• "Stimulates collagen production": Although widely used by many brands, in the US market, the FDA considers "collagen synthesis" as an alteration of skin structure function, strictly approaching the drug claim boundary. It is recommended to change to "supports the skin's natural elastic appearance" or "delivers a plumper appearance."

• "Botox-like effect" / "Comparable to injectable lifting": Triggers drug claims in most markets; must be completely avoided.

• "Rebuilds the dermal support network": Explicitly points to dermal structure, falling under the drug category.

IV. "Spot-Lightening / Whitening" Claims: The Most Complex Multi-Market Compliance Zone

Spot-lightening and whitening claims represent the most complex multi-market compliance zone among the three directions, with the largest regulatory differences and the highest risk of missteps in multi-market sales.

EU: Hydroquinone Banned, Whitening Actives Restricted

The EU completely bans hydroquinone in skincare (creams, serums, spot-removing products, body lotions) for whitening purposes, with the only exception being specific professional nail products under certain conditions. For brightening products targeting the EU market, ingredients and claims usually must adopt expressions like "radiance-enhancing" or "tone-evening," rather than "bleaching" or "whitening."

In 2024, the EU further restricted two mainstream brightening ingredients: Under Commission Regulation (EU) 2024/996, Alpha-Arbutin is limited to 2% for facial use and 0.5% for body lotions; Arbutin is limited to 7% (facial). Products not complying with the new restrictions cannot be placed on the market from February 1, 2025, and cannot be made available on the market from November 1, 2025.

US: Context-Driven, Dual-Identity Risk

The US FDA classifies products containing specific brightening actives (like hydroquinone used in OTC products) as OTC drugs, which must comply with corresponding drug standards, not cosmetic standards. For brightening ingredients like niacinamide and Vitamin C, claims must strictly remain at the "appearance level":

• Compliant: "Evens the appearance of skin tone," "Reduces the look of dullness," "Brightens complexion."

• Risk: "Inhibits melanin production," "Intervenes in tyrosinase activity" (implies biological intervention mechanisms, potentially deemed drug claims).

China NMPA: Whitening is a Special Efficacy, Requires Separate Registration

Chinese regulations classify "whitening and spot-removing" as Special Cosmetics, requiring special registration with the NMPA. This means the product must provide efficacy evaluation reports, safety assessment documents, and can only be marketed after NMPA approval. Any serum containing whitening-related claims sold in the Chinese market without special cosmetic registration is illegal.

V. Quick Reference Table for Global Market Claim Boundaries

Claim Type	US FDA	EU	China NMPA	Safe Expression Template
Anti-Wrinkle	"Appearance improvement" OK; "Structural repair" crosses the line.	Must have scientific evidence; no drug-action implications allowed.	General efficacy; must upload efficacy summary.	"Reduces the appearance of fine lines"
Firming / Lifting	Appearance descriptions OK; collagen synthesis claims must be cautious.	Appearance improvement OK; internal structural alteration must be avoided.	General efficacy; must upload efficacy summary.	"Skin looks firmer and more elastic"
Spot-Lightening / Whitening	Products with specific actives may upgrade to OTC drugs.	Hydroquinone banned; Alpha-Arbutin capped at 2%.	Special Cosmetic; requires NMPA registration.	"Evens skin tone appearance" / "Brightens complexion"
Stimulates Collagen	High Risk (Implies structural function alteration).	High Risk	High Risk	"Supports skin's natural elastic appearance"
Reverses Aging	Red Line	Red Line	Red Line	Absolutely Avoid

VI. Serum Substantiation System: Whatever You Say, You Must Be Able to Prove It

In the three major markets, claim compliance is not just about "appropriate wording"; it must be backed by corresponding data documentation.

In 2025, supporting claims requires solid evidence, which can include:

• Consumer perception tests (collecting user perception data via questionnaires).

• Scientific publications (using the latest clinical and scientific research to support claims).

• Experimental studies (e.g., in vitro, computer simulations, or ex vivo studies to prove the efficacy of ingredients and formulations).

This means: the phrase "skin looks younger" requires a corresponding before-and-after comparison data of L*a*b* color space values measured by a chromameter, or a statistically significant report from a consumer questionnaire—not the subjective judgment of a formulation engineer.

Can your manufacturing partner hold this tolerance in production?

A specification that passes on the bench and drifts at scale is a process-control problem, not a formula problem. We treat this as an engineering parameter with a measured control window, not a QA checkbox.

Our lines pair in-process measurement with batch-level documentation, so what is approved in the sample is what ships in the order — reorder after reorder.

By collaborating with Explore our skincare manufacturing capabilities you gain access to industry-leading expertise and innovative formulations that set your brand apart in the competitive global market. Send us your current spec and observed deviation — we will tell you whether it is a formulation fix or a process fix.